Business Context and Reporting Period
Company: Collegium Pharmaceutical, Inc.
Filing Type: Form 8-K (Current Report)
Date: October 25, 2016
Context: The Company is a specialty pharmaceutical firm developing abuse-deterrent products using its DETERx platform. Its primary product, Xtampza (oxycodone), received FDA approval in April 2016 and launched commercially in June 2016. This filing announces the commencement of an underwritten public offering of common stock and provides preliminary financial data for the quarter ended September 30, 2016.
Key Financial Metrics
- Revenue (Preliminary): Approximately $400,000 for the three months ended September 30, 2016.
- Cash and Cash Equivalents: Approximately $90.9 million as of September 30, 2016.
- Profit/Loss: The filing does not provide a clear value for net income or loss for the period.
- Debt: The filing does not provide a clear value for outstanding debt as of the reporting date, noting that operations since the May 2015 IPO have been funded primarily through equity offerings.
- Liquidity: Management believes current cash resources, expected Xtampza revenue, and proceeds from the current offering will fund operations into 2019.
Material Changes and Operational Updates
- Capital Raise: Commenced an underwritten public offering with Jefferies LLC and Piper Jaffray & Co. as joint book-running managers. Includes a 30-day option for underwriters to purchase up to an additional 15% of shares.
- Product Launch: Xtampza was commercially launched on June 20, 2016. A New Drug Submission for Health Canada was submitted on October 3, 2016.
- Label Enhancement: On October 5, 2016, the Company submitted a Supplemental New Drug Application to the FDA to include comparative oral pharmacokinetic data regarding physical manipulation of Xtampza versus OxyContin OP.
- New Partnership: In May 2016, entered into an exclusive license agreement with BioDelivery Science International, Inc. to commercialize Onsolis in the U.S., with a planned launch in the second half of 2017 pending FDA approval.
Guidance, Outlook, and Risks
Outlook: Management expects to have adequate cash resources to fund operations into 2019, contingent on revenue from Xtampza and the success of the current public offering. The Company has not generated significant revenue since 2011 and continues to incur significant research and development expenses.
Risks and Contingencies:
- Regulatory approval and label restrictions for products.
- Market acceptance and competition, specifically from OxyContin OP.
- Reimbursement negotiations with payors (e.g., UnitedHealth, Cigna).
- Potential patent infringement litigation, including with Purdue Pharma, L.P.
- Reliance on third-party suppliers and manufacturers.
Unusual Items: The financial data provided ($400,000 revenue, $90.9 million cash) is preliminary, unaudited, and subject to completion of quarterly closing procedures.
Investor Verification Checklist
- Verify the final terms and total proceeds of the underwritten public offering announced on October 25, 2016.
- Confirm the audited revenue figures for the quarter ended September 30, 2016, once the 10-Q is filed.
- Monitor the status of the Supplemental New Drug Application submitted to the FDA on October 5, 2016.
- Track reimbursement agreements and formulary placements with major payors like UnitedHealth and Cigna.
- Review updates on the FDA Prior Approval Supplement required for the manufacturing transfer of Onsolis.